A multicentre, open-label phase 2 study to evaluate the efficacy and safety of pembrolizumab in the treatment of advanced, progressive adrenocortical carcinoma

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-517205-82-00

Acronym

PEMBR-01

Enrollment

Registered

2024-09-22

Start date

2023-01-20

Completion date

Unknown

Last updated

2025-01-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

adrenocortical carcinoma

Brief summary

Objective Response Rate (ORR), Progression-Free Survival (PFS), Duration of Response (DoR), Overall Survival (OS)

Detailed description

Quality of life assesed by QLQ-C30 questionnaire, Number of Adverse Events and Serious Adverse Events (AEs and SAEs) related and unrelated to treatment according to CTCAE

Interventions

DRUGPEMBROLIZUMAB

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Objective Response Rate (ORR), Progression-Free Survival (PFS), Duration of Response (DoR), Overall Survival (OS)	—

Secondary

Measure	Time frame
Quality of life assesed by QLQ-C30 questionnaire, Number of Adverse Events and Serious Adverse Events (AEs and SAEs) related and unrelated to treatment according to CTCAE	—

Countries

Poland

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026